Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
A 59-year-old female with an unresectable, large pancreatic tumor (10.0 x 8.0 cm(2) on CT scan) underwent nonmyeloablative allogeneic peripheral-blood stem-cell transplantation from her HLA-identical sibling. Pronounced tumor regression and relief from pain without acute graft-versus-host disease (GVHD) were observed following transplantation. The patient is surviving (more than 300 days) after transplantation, with extensive chronic GVHD, and has tumor regression with an 80% reduction in tumor size. The observed clinical course may suggest a graft-versus-tumor effect on the pancreatic tumor following allogeneic stem-cell transplantation.
Omuro
Y
Y
Department of Chemotherapy, Tokyo Metropolitan Komagome Hospital, Hokomagome, Bunkyo-ku, Tokyo, Japan.
Matsumoto
G
G
Sasaki
T
T
Tanaka
Y
Y
Maeda
Y
Y
Sakamaki
H
H
Hiruma
K
K
Tsuruta
K
K
Takahashi
T
T
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000628:therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D019520:Living Donors; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D035781:Siblings; D033581:Stem Cell Transplantation / Q000379:methods*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D019172:Transplantation Conditioning / Q000379:methods; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine